Commave Therap Drug Patent Portfolio
Commave Therap owns 1 orange book drug protected by 6 US patents Given below is the list of Commave Therap's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10584112 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
US10584113 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
US10759778 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
US10858341 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
US10954213 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
US9079928 | Methylphenidate-oxoacid conjugates, processes of making and using the same | 27 Jul, 2032 | Active |
Latest Legal Activities on Commave Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Commave Therap.
Activity | Date | Patent Number |
---|---|---|
transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9079928 |
Payment of Maintenance Fee, 4th Year, Large Entity | 31 Dec, 2023 | US10759778 |
Payment of Maintenance Fee, 4th Year, Large Entity | 31 Dec, 2023 | US10858341 |
transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US9079928 |
Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2023 | US10584112 |
Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2023 | US10584113 |
Email Notification
Critical
| 17 May, 2023 | US9079928 |
Electronic Review
Critical
| 17 May, 2023 | US9079928 |
Second letter to regulating agency to determine regulatory review period | 16 May, 2023 | US9079928 |
Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jan, 2023 | US9079928 |
Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2022 | US9079928 |
Initial letter Re: PTE Application to regulating agency | 27 Jan, 2022 | US9079928 |
Patent Issue Date Used in PTA Calculation
Critical
| 23 Mar, 2021 | US10954213 |
Recordation of Patent Grant Mailed
Critical
| 23 Mar, 2021 | US10954213 |
Email Notification
Critical
| 05 Mar, 2021 | US10954213 |
Commave Therap's Family Patents
Commave Therap Drug List
Given below is the complete list of Commave Therap's drugs and the patents protecting them.
1. Azstarys
Azstarys is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10584112 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(12 years from now)
| Active |
US10584113 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(12 years from now)
| Active |
US10759778 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(12 years from now)
| Active |
US10858341 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(12 years from now)
| Active |
US10954213 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(12 years from now)
| Active |
US9079928 | Methylphenidate-oxoacid conjugates, processes of making and using the same |
27 Jul, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azstarys's drug page